The Long-Term Safety and Tolerability of ABT-089 in Children With Attention Deficit-Hyperactivity Disorder (ADHD): An Open-Label Extension Study.

Trial Profile

The Long-Term Safety and Tolerability of ABT-089 in Children With Attention Deficit-Hyperactivity Disorder (ADHD): An Open-Label Extension Study.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 09 Aug 2016

At a glance

  • Drugs Pozanicline (Primary)
  • Indications Attention-deficit hyperactivity disorder
  • Focus Therapeutic Use
  • Sponsors Abbott Laboratories
  • Most Recent Events

    • 14 Sep 2008 Actual patient number (283) added as reported by ClinicalTrials.gov.
    • 14 Sep 2008 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 01 Jan 2008 Status changed from initiated to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top